{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enhertu&page=2", "query": { "intervention": "Enhertu", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Enhertu&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-22T14:46:14.473Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06533826", "title": "TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "HER2-low Breast Cancer", "Metastatic Breast Cancer", "HER2-negative Breast Cancer" ], "interventions": [ { "name": "Trastuzumab Deruxtecan", "type": "DRUG" }, { "name": "Datopotamab Deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ana C Garrido-Castro, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 357, "start_date": "2024-10-29", "completion_date": "2038-08-01", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-22T14:46:14.473Z", "location_count": 11, "location_summary": "Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06533826" }, { "nct_id": "NCT07137416", "title": "Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Invasive Breast Carcinoma", "Locally Advanced Breast Carcinoma", "Metastatic Breast Carcinoma", "Metastatic HER2-Low Breast Carcinoma", "Metastatic HER2-Positive Breast Carcinoma", "Metastatic Hormone Receptor-Positive Breast Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Triple-Negative Breast Carcinoma", "Unresectable Breast Carcinoma", "Unresectable HER2-Low Breast Carcinoma", "Unresectable HER2-Positive Breast Carcinoma", "Unresectable Hormone Receptor-Positive Breast Carcinoma", "Unresectable Malignant Solid Neoplasm", "Unresectable Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Pidnarulex", "type": "DRUG" }, { "name": "Radiologic Imaging Procedure", "type": "PROCEDURE" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2026-10-05", "completion_date": "2028-01-10", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-09-22T14:46:14.473Z", "location_count": 2, "location_summary": "Boston, Massachusetts • St Louis, Missouri", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07137416" }, { "nct_id": "NCT05650879", "title": "ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2 Mutant Non-small Cell Lung Cancer", "HER2-positive Metastatic Breast Cancer", "HER2 Gene Mutation", "HER2 Amplification" ], "interventions": [ { "name": "ELVN-002", "type": "DRUG" }, { "name": "Fam-Trastuzumab Deruxtecan-Nxki", "type": "DRUG" }, { "name": "Trastuzumab emtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Enliven Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 198, "start_date": "2023-03-20", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2025-07-15", "last_synced_at": "2026-09-22T14:46:14.473Z", "location_count": 5, "location_summary": "Aurora, Colorado • Orlando, Florida • Plantation, Florida + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Plantation", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05650879" }, { "nct_id": "NCT05765851", "title": "A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "DS-1103a", "type": "DRUG" }, { "name": "T-DXd", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 108, "start_date": "2023-05-30", "completion_date": "2030-05-15", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-22T14:46:14.473Z", "location_count": 4, "location_summary": "Sarasota, Florida • Providence, Rhode Island • Salt Lake City, Utah + 1 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05765851" }, { "nct_id": "NCT04294628", "title": "Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Metastatic Malignant Solid Neoplasm", "Refractory Malignant Solid Neoplasm", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2020-09-01", "completion_date": "2027-01-19", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-09-22T14:46:14.473Z", "location_count": 6, "location_summary": "Bethesda, Maryland • Boston, Massachusetts • New York, New York + 2 more", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04294628" }, { "nct_id": "NCT04379596", "title": "Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Volrustomig", "type": "BIOLOGICAL" }, { "name": "Rilvegostomig", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 452, "start_date": "2020-06-03", "completion_date": "2027-05-04", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-22T14:46:14.473Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04379596" }, { "nct_id": "NCT06439693", "title": "The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer Female", "Breast Cancer", "Breast Cancer Metastatic", "Estrogen Receptor-positive Breast Cancer", "HER2-positive Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Phesgo", "type": "DRUG" }, { "name": "T-DM1", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Trastuzumab Deruxtecan", "type": "DRUG" }, { "name": "Trastuzumab Subcutaneous Subcutaneous", "type": "DRUG" }, { "name": "Tucatinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2024-08-08", "completion_date": "2033-03-30", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-09-22T14:46:14.473Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06439693" }, { "nct_id": "NCT04616560", "title": "Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Desmoplastic Small Round Cell Tumor", "Osteosarcoma", "Recurrent Desmoplastic Small Round Cell Tumor", "Recurrent Kidney Wilms Tumor", "Recurrent Osteosarcoma", "Refractory Desmoplastic Small Round Cell Tumor", "Refractory Wilms Tumor", "Wilms Tumor" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "12 Years to 39 Years" }, "enrollment_count": 55, "start_date": "2021-03-08", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-09-22T14:46:14.473Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04616560" }, { "nct_id": "NCT05868226", "title": "PRE-ISPY Phase I/II Oncology Platform Program", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "Metastatic Cancer", "Metastatic Breast Cancer", "Metastatic", "HER2-positive Metastatic Breast Cancer", "HER2 Mutation-Related Tumors", "HER-2 Protein Overexpression", "HER2-negative Breast Cancer", "Triple Negative Breast Cancer", "HR Positive", "Hormone Receptor-positive Breast Cancer", "Estrogen Receptor Positive Tumor", "Progesterone Receptor-positive Breast Cancer", "Hormone Receptor Negative Breast Carcinoma", "Solid Tumor", "Solid Tumor, Adult", "Solid Carcinoma", "HER2 Low Breast Cancer", "HER2 Low Breast Carcinoma", "ER Positive Breast Cancer", "PR-positive Breast Cancer", "Minimal Residual Disease", "Colo-rectal Cancer", "Colon Cancer", "Rectal Cancer", "ctDNA Monitoring", "Colorectal Neoplasms", "Colonic Neoplasms", "Rectal Neoplasms", "Neoplasm, Residual", "Adenocarcinoma of Colon", "Adenocarcinoma" ], "interventions": [ { "name": "ALX148", "type": "DRUG" }, { "name": "Fam-Trastuzumab Deruxtecan-Nxki", "type": "DRUG" }, { "name": "Zanidatamab", "type": "DRUG" }, { "name": "Tucatinib", "type": "DRUG" }, { "name": "TTX-MC138", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QuantumLeap Healthcare Collaborative", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 280, "start_date": "2023-02-15", "completion_date": "2031-12-30", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-22T14:46:14.473Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05868226" }, { "nct_id": "NCT07553390", "title": "Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan (T-DXd)", "type": "DRUG" }, { "name": "Rimiducid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-10-01", "completion_date": "2038-03-30", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-09-22T14:46:14.473Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07553390" } ] }